Get the Stockscreener App
13.16
1.02%
-0.115
Adaptive Biotechnologies Corp stock is traded at $13.16, with a volume of 108.31K.
It is down -1.02% in the last 24 hours and down -18.10% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$13.28
Open:
$13.1
24h Volume:
108.31K
Relative Volume:
0.05
Market Cap:
$2.02B
Revenue:
$276.98M
Net Income/Loss:
$-59.46M
P/E Ratio:
-33.02
EPS:
-0.3987
Net Cash Flow:
$-48.95M
1W Performance:
+5.58%
1M Performance:
-18.10%
6M Performance:
-1.61%
1Y Performance:
+73.88%
1-Day Range:
$12.97
$13.21
1-Week Range:
$12.69
$13.88
52-Week Range:
$6.675
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
13.14 | 2.04B | 276.98M | -59.46M | -48.95M | -0.3987 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.83 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.60 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.84 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.62 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies COO Rubinstein sells $762k in ADPT stock - Investing.com
Adaptive Biotechnologies (ADPT) COO exercises options and sells 57,180 shares - Stock Titan
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
ADPT (NASDAQ: ADPT) lists 140,666 RSUs and 329,600 PSUs in Rule 144 filing - Stock Titan
Insider sales at Adaptive Biotechnologies (NASDAQ: ADPT) include 122,523 RSUs - Stock Titan
18,672 RSUs registered for sale by filer (ADPT) via Morgan Stanley - Stock Titan
Chad Robins lists multiple ADPT share sales in Form 144 (ADPT) - Stock Titan
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance
Adaptive Biotechnologies Corporation $ADPT Shares Sold by Braidwell LP - MarketBeat
Adaptive Biotechnologies CFO Piskel sells $245,910 in shares By Investing.com - Investing.com Nigeria
Insider Sell: Michelle Griffin Sells 15,394 Shares of Adaptive B - GuruFocus
Francis Lo Sells 30,593 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells 470,167 Shares of Stock - MarketBeat
Adaptive Biotechnologies’ president Rubinstein sells $2.37 million in ADPT stock - Investing.com
Adaptive Biotechnologies director Griffin sells $214,130 in stock - Investing.com
Adaptive Biotechnologies CCO Bobulsky sells $544k in ADPT stock By Investing.com - Investing.com Canada
Adaptive Biotechnologies CCO Bobulsky sells $544k in ADPT stock - Investing.com Australia
Adaptive Biotechnologies Executives Sell Shares to Cover Tax Obligations - TradingView
Adaptive Biotechnologies’ chief commercial officer sells $831k in stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CFO Piskel sells $245,910 in shares - Investing.com
Adaptive Biotechnologies’ chief people officer Lo sells $430k in stock - Investing.com Canada
Adaptive Biotechnologies’ chief people officer Lo sells $430k in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies’ chief commercial officer sells $831k in stock - Investing.com
Adaptive Biotechnologies’ chief scientific officer sells $6.19 million in stock - Investing.com
Adaptive Biotechnologies CEO Robins sells $6.19 million in ADPT stock - Investing.com
Adaptive Biotechnologies Executives Sell Shares for Tax Obligations - TradingView
Adaptive Biotechnologies Hits Day Low of $12 Amid Price Pressure - Markets Mojo
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap UpWhat's Next? - MarketBeat
Adaptive Biotechnologies (ADPT) CFO executes mandated 18,672-share sale for RSU tax withholding - Stock Titan
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 9.9%Here's Why - MarketBeat
Francis Lo reports multiple 10b5-1 share sales for ADPT (NASDAQ: ADPT) - Stock Titan
Michelle Griffin sells 48,044 ADPT shares (ADPT) for $735K - Stock Titan
ADPT (Adaptive Biotechnologies) NonCurrent Deferred Revenue : $1.0 Mil (As of Dec. 2025) - GuruFocus
Piper Sandler reiterates Adeptus Biotechnologies stock rating at overweight By Investing.com - Investing.com India
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 19,460 Shares of Stock - MarketBeat
Adaptive Biotechnologies Executive Sells Over $1.2 Million in Company Stock - TradingView
Piper Sandler reiterates Adeptus Biotechnologies stock rating at overweight - Investing.com
[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity - Stock Titan
Lo Francis, chief people officer at Adaptive Biotechnologies, sells $574k in ADPT By Investing.com - Investing.com South Africa
Lo Francis, chief people officer at Adaptive Biotechnologies, sells $574k in ADPT - Investing.com Nigeria
Adaptive Biotechnologies (ADPT) HR chief offloads shares to cover RSU taxes - Stock Titan
Adaptive Biotechnologies Exec Sells Shares to Cover Tax - TradingView
Do Insider Sales Align With Adaptive Biotechnologies' (ADPT) MRD-Driven Momentum and Long-Term Strategy? - simplywall.st
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Director at Adaptive Biotechnologies (ADPT) receives 15,625-share award - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) grants 44,063 shares to Chief People Officer - Stock Titan
Adaptive Biotechnologies (ADPT) CFO receives 61,875-share stock grant - Stock Titan
Director Michelle Renee Griffin receives 15,625 ADPT shares in stock grant - Stock Titan
Loss Report: Will Adaptive Biotechnologies Corporation stock go up in YEAR - baoquankhu1.vn
Insider Sales Put Focus On Adaptive Biotechnologies Growth Story And Dilution Risk - Yahoo Finance
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares By Investing.com - Investing.com UK
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):